Hantavirus vaccine in 2026?
Oui
2%
Non
99%
Variation 24 h
-1.7 pts
- Volume
- $154K
- Volume 24 h
- $10.7K
- Liquidité
- $63.3K
- Mis à jour
- 15 nov. 2026 · 12:50 UTC
Probabilité dans le temps
Probabilité du marché
IA PolyForecast
L’historique des prix est encore en cours de collecte pour cette période.
Écart IA dans le temps
Pourquoi l’IA prévoit cette probabilité
Le raisonnement de l’IA apparaît ici dès qu’une prévision est générée pour ce marché.
Dernières actualités pertinentes
Aucune actualité pertinente trouvée.
À propos de ce marché
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Données de marché fournies par Polymarket. PolyForecast n’est pas affilié à Polymarket.